José Luis Millán Selected Research

Osteomalacia

4/2016	Alkaline Phosphatase and Hypophosphatasia.
3/2015	Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase.
11/2014	Ablation of osteopontin improves the skeletal phenotype of phospho1(-/-) mice.
10/2014	Tissue-nonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl(-/-) mouse model of infantile hypophosphatasia.
10/2013	The role of phosphatases in the initiation of skeletal mineralization.
7/2013	In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin.
1/2013	Multisystemic functions of alkaline phosphatases.
8/2012	Enzyme replacement prevents enamel defects in hypophosphatasia mice.
3/2012	Enzyme-replacement therapy in life-threatening hypophosphatasia.
11/2011	Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José Luis Millán Research Topics

Disease

32	Hypophosphatasia 12/2021 - 03/2004
14	Rickets (Rachitis) 04/2016 - 06/2008
14	Osteomalacia 04/2016 - 06/2005
10	Seizures (Absence Seizure) 12/2021 - 01/2011
7	Vascular Calcification 01/2020 - 04/2010
5	Sepsis (Septicemia) 01/2020 - 01/2017
5	Body Weight (Weight, Body) 01/2017 - 05/2007
4	Chronic Renal Insufficiency 07/2021 - 11/2009
4	Infantile Hypophosphatasia 10/2014 - 11/2009
3	Inflammation (Inflammations) 10/2018 - 03/2013
3	Craniosynostoses (Craniosynostosis) 04/2016 - 10/2014
3	Dysbiosis 05/2014 - 01/2013
2	Wounds and Injuries (Trauma) 01/2022 - 10/2013
2	Hyperphosphatemia 07/2021 - 01/2018
2	Hypocalcemia 07/2021 - 03/2012
2	Dental Enamel Hypomineralization 01/2021 - 08/2012
2	Osteogenesis Imperfecta (Lobstein Disease) 11/2015 - 05/2015
2	Alzheimer Disease (Alzheimer's Disease) 01/2015 - 01/2013
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2014 - 03/2013
2	Colitis 01/2013 - 02/2011
2	Hypercalcemia (Milk Alkali Syndrome) 09/2012 - 06/2008
2	Obesity 12/2011 - 05/2007
2	Osteoarthritis 04/2010 - 11/2004
2	Ankylosis 04/2010 - 11/2004
1	Pathologic Processes 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 07/2021
1	Injection Site Reaction 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 12/2020
1	Liver Diseases (Liver Disease) 12/2020
1	Neuroinflammatory Diseases 01/2020
1	Chronic Kidney Disease-Mineral and Bone Disorder (Renal Rickets) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2018
1	Nervous System Diseases (Neurological Disorders) 01/2017
1	Pseudoxanthoma Elasticum (Gronblad Strandberg Syndrome) 01/2017
1	Epilepsy (Aura) 01/2017
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2017
1	Atherosclerosis 01/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Metabolic Bone Diseases (Osteopenia) 10/2016
1	Melanoma (Melanoma, Malignant) 05/2016
1	Muscle Weakness 04/2016
1	Stomatognathic Diseases (Dental Disease) 12/2015
1	Campomelic Dysplasia 11/2015
1	Craniofacial Abnormalities 09/2015
1	Hypertension (High Blood Pressure) 05/2015
1	Cardiomegaly (Heart Hypertrophy) 05/2015
1	Weight Gain 01/2015
1	Growth Disorders 11/2014
1	Spontaneous Fractures (Pathological Fracture) 11/2014
1	Scoliosis 11/2014

Drug/Important Bio-Agent (IBA)

49	Alkaline PhosphataseIBA 12/2021 - 11/2004
20	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 12/2021 - 06/2008
14	EnzymesIBA 07/2021 - 11/2009
13	diphosphoric acid (pyrophosphoric acid)IBA 01/2021 - 11/2009
8	IsoenzymesIBA 10/2018 - 06/2008
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2010
6	MineralsIBA 01/2021 - 03/2004
5	asfotase alfaIBA 01/2021 - 08/2011
5	LipopolysaccharidesIBA 10/2018 - 04/2013
4	Vitamin B 6IBA 10/2016 - 01/2013
4	VitaminsIBA 03/2015 - 08/2012
3	Biological ProductsIBA 01/2022 - 11/2009
3	Phosphates (Orthophosphate)IBA 12/2020 - 05/2016
3	SBI-425IBA 01/2020 - 01/2017
3	CalciumIBA 01/2020 - 05/2016
3	OsteopontinIBA 11/2014 - 06/2003
3	Durapatite (Hydroxylapatite)IBA 10/2013 - 09/2006
3	Protein Isoforms (Isoforms)IBA 04/2013 - 11/2009
2	Indicators and Reagents (Reagents)IBA 01/2020 - 01/2011
2	LipidsIBA 01/2017 - 05/2007
2	Adenosine Triphosphate (ATP)IBA 10/2016 - 01/2015
2	CollagenIBA 05/2015 - 10/2013
2	Bacterial ToxinsIBA 01/2015 - 01/2005
2	PyridoxalIBA 01/2015 - 11/2009
2	Pharmaceutical PreparationsIBA 03/2012 - 11/2009
2	nucleotide pyrophosphataseIBA 06/2005 - 04/2004
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 06/2005 - 04/2004
1	CreatinineIBA 07/2021
1	Lipid AIBA 12/2020
1	IonsIBA 01/2020
1	Warfarin (Coumadin)FDA LinkGeneric 01/2020
1	Choline (Choline Chloride)IBA 07/2019
1	Toll-Like Receptor 4IBA 10/2018
1	Neuraminidase (Sialidase)IBA 10/2018
1	Adenine FDA LinkGeneric 01/2018
1	A-factor (Streptomyces)IBA 01/2018
1	oil red OIBA 01/2017
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017
1	Toll-Like Receptor AgonistsIBA 01/2017
1	Hypoxanthine Phosphoribosyltransferase (Hypoxanthine Guanine Phosphoribosyltransferase)IBA 05/2015
1	Adenosine (Adenocard)FDA LinkGeneric 01/2015
1	tau Proteins (tau Protein)IBA 01/2015
1	Amino Acids FDA Link 01/2015
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2014

Therapy/Procedure

5	Enzyme Replacement Therapy 12/2021 - 06/2008
4	Therapeutics 01/2014 - 02/2011
1	Injections 01/2021
1	Ligation 01/2020
1	Punctures 01/2020
1	Sutures (Suture) 10/2014